ADA Scientific Sessions 2025 Abstract
Targeting Activin Type II Receptors—Develop Monoclonal Antibodies LAE102, LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction
Experiments in animalsInterventions
Papers by Chris Lu
2 results
- ADA Scientific Sessions 2025 Abstract
First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy Volunteers
Trial in peopleInterventions